Rituximab and Intravenous Immunoglobulins for Relapsing Postinfectious Opsoclonus-Myoclonus Syndrome

Pediatric Neurology

Volumn 39, Issue 3, 2008, Pages 213-217

  Leen, Wilhelmina G ^a   Weemaes, Corry M ^a   Verbeek, Marcel M ^a   Willemsen, Michèl A ^a   Rotteveel, Jan J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; DIAZEPAM; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; PHENYTOIN; RITUXIMAB;

ANAMNESIS; ARTICLE; ATAXIA; B LYMPHOCYTE; BODY TEMPERATURE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DRUG RESPONSE; DRUG SUBSTITUTION; DYSMETRIA; ECHO VIRUS; ELECTROENCEPHALOGRAM; FEMALE; GAIT DISORDER; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION COMPLICATION; LABORATORY TEST; LYMPHOCYTE DEPLETION; MONOTHERAPY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS MYOCLONUS SYNDROME; PARAINFLUENZA VIRUS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; OPSOCLONUS-MYOCLONUS SYNDROME; RECURRENCE; TREATMENT OUTCOME;

EID: 49749087581     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.05.015     Document Type: Article

References (15)

1. Wong A. An update on opsoclonus. Curr Opin Neurol 20 (2007) 25-31
2. Yiu V.W., Kovithavongs T., McGonigle L.F., and Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 24 (2001) 72-74
3. Burke M.J., and Cohn S.L. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pedriatr Blood Cancer 50 (2008) 679-680
4. Bell J., Moran C., and Blatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 50 (2008) 370-371
5. Pranzatelli M.R., Tate E.D., Travelstead A.L., and Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 115 (2005) e115-e119
6. Pranzatelli M.R., Tate E.D., Travelstead A.L., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 28 (2006) 585-593
7. Verbeek M.M., De Jong D., and Kremer H.F. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 40 (2003) 25-40
8. Verbeek M.M., de Reus H.P., and Weykamp C.W. Comparison of methods for the detection of oligoclonal bands in cerebrospinal fluid and serum: Results of the Dutch Quality Control Survey. Clin Chem 48 (2002) 1578-1580
9. Reiber H., and Peter J.B. Cerebrospinal fluid analysis: Disease-related data patterns and evaluation programs. J Neurol Sci 184 (2001) 101-122
10. Petereit H.F., Moeller-Hartmann W., Reske D., and Rubbert A. Rituximab in a patient with multiple sclerosis-Effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 117 (2008) 339-403
11. Pranzatelli M.R., Travelstead A.L., Tate E.D., Allison T.J., and Verhulst S.J. CSF B-cell expansion in opsoclonus-myoclonus syndrome: A biomarker of disease activity. Mov Disorders 19 (2004) 770-777
12. Meinl E., Krumbholz M., and Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic options. Ann Neurol 59 (2006) 880-892
13. Park-Min K.H., Serbina N.V., Yang W., et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26 (2007) 67-78
14. Tedder T.F., Baras A., and Xiu Y. +Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 28 (2006) 351-364
15. Clynes R. IVIg therapy: Interfering with interferon-gamma. Immunity 26 (2007) 4-6